See more : SHL Telemedicine Ltd. (SHLTN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Geron Corporation (GERN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Geron Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Propel Holdings Inc. (PRLPF) Income Statement Analysis – Financial Results
- WH Smith PLC (SMWH.L) Income Statement Analysis – Financial Results
- DMCC Speciality Chemicals Limited (DMCC.BO) Income Statement Analysis – Financial Results
- Tempus Capital Inc. (TEMP.CN) Income Statement Analysis – Financial Results
- PFA Invest Balance A (PFIBAA.CO) Income Statement Analysis – Financial Results
Geron Corporation (GERN)
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 237.00K | 596.00K | 1.39M | 253.00K | 460.00K | 1.07M | 1.07M | 6.16M | 36.37M | 1.15M | 1.28M | 2.71M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 6.61M | 5.40M | 6.80M | 7.30M | 5.30M |
| Cost of Revenue | 123.74M | 868.00K | 783.00K | 50.05M | 51.27M | 12.72M | 8.44M | 14.70M | 9.57M | 8.90M | 9.13M | 25.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.65M | -3.70M | -1.70M | -1.60M | -1.20M |
| Gross Profit | -123.50M | -272.00K | 610.00K | -49.80M | -50.81M | -11.66M | -7.37M | -8.53M | 26.80M | -7.75M | -7.85M | -22.47M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 11.26M | 9.10M | 8.50M | 8.90M | 6.50M |
| Gross Profit Ratio | -52,110.97% | -45.64% | 43.79% | -19,683.40% | -11,046.09% | -1,093.53% | -692.21% | -138.48% | 73.68% | -671.99% | -611.93% | -829.42% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 170.40% | 168.52% | 125.00% | 121.92% | 122.64% |
| Research & Development | 125.05M | 95.52M | 85.73M | 51.49M | 52.07M | 13.43M | 11.03M | 18.05M | 17.83M | 20.71M | 23.16M | 51.37M | 69.32M | 61.69M | 57.62M | 53.66M | 54.62M | 41.23M | 35.08M | 30.08M | 25.55M | 31.57M | 29.02M | 23.55M | 20.60M | 15.60M | 15.10M | 14.30M |
| General & Administrative | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Other Expenses | 0.00 | 1.00M | 1.10M | 168.00K | -69.00K | -154.00K | 0.00 | 0.00 | 1.31M | 0.00 | 0.00 | 5.45M | 5.45M | 35.00M | 57.62M | 0.00 | 54.62M | 0.00 | -5.87M | 45.15M | 0.00 | 0.00 | 0.00 | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| Operating Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 37.47M | 29.90M | 21.10M | 19.80M | 18.70M |
| Cost & Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 32.82M | 26.20M | 19.40M | 18.20M | 17.50M |
| Interest Income | 18.15M | 2.53M | 527.00K | 1.83M | 4.22M | 3.29M | 1.42M | 1.19M | 677.00K | 373.00K | 951.00K | 3.10M | 1.02M | 2.05M | 1.37M | 5.54M | 10.79M | 8.70M | 4.66M | 1.55M | 1.81M | 2.55M | 5.86M | 5.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.31M | 6.88M | 3.74M | 760.00K | 0.00 | 0.00 | 77.00K | 83.00K | 88.00K | 82.00K | 56.00K | 233.00K | 237.00K | 98.00K | 143.00K | 93.00K | 102.00K | 130.00K | 464.00K | 672.00K | 736.00K | 757.00K | 1.00M | 12.28M | 0.00 | 900.00K | 0.00 | 400.00K |
| Depreciation & Amortization | 1.03M | 868.00K | 783.00K | 935.00K | 776.00K | 59.00K | 76.00K | 81.00K | 56.00K | 47.00K | 320.00K | 830.00K | 1.58M | 1.61M | 1.75M | 2.42M | 1.93M | 1.59M | 3.74M | 3.91M | 4.12M | 4.59M | 4.37M | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| EBITDA | -174.78M | -134.15M | -111.59M | -73.92M | -67.77M | -26.96M | -29.18M | -30.57M | 803.00K | -35.62M | -38.06M | -67.82M | -95.04M | -109.67M | -68.29M | -59.91M | -62.84M | -47.36M | -35.85M | -32.23M | -26.06M | -31.11M | -30.65M | -21.56M | -17.10M | -10.90M | -9.30M | -11.00M |
| EBITDA Ratio | -73,747.68% | -22,654.19% | -8,010.70% | -29,611.46% | -15,761.96% | -3,051.88% | -2,613.99% | -477.99% | 3.92% | -3,117.00% | -2,823.46% | -2,434.81% | -3,388.72% | -1,160.74% | -4,078.27% | -2,320.37% | -1,001.86% | -1,623.19% | -13,736.21% | 1,226.97% | -2,153.24% | -2,492.79% | -517.65% | -326.21% | 116.67% | -200.00% | -152.05% | -241.51% |
| Operating Income | -193.94M | -138.55M | -114.00M | -76.91M | -72.51M | -31.07M | -29.26M | -30.65M | -559.00K | -36.31M | -38.96M | -71.76M | -96.12M | -111.17M | -70.23M | -67.04M | -62.84M | -47.36M | -37.71M | -81.29M | -30.18M | -35.70M | -35.02M | -26.21M | -20.80M | -12.60M | -10.90M | -12.20M |
| Operating Income Ratio | -81,832.91% | -23,246.64% | -8,183.70% | -30,400.40% | -15,761.96% | -2,914.92% | -2,746.95% | -497.34% | -1.54% | -3,149.35% | -3,036.48% | -2,648.87% | -3,942.41% | -3,120.04% | -4,069.18% | -2,391.87% | -824.44% | -1,445.22% | -13,003.45% | -7,719.37% | -2,570.70% | -2,860.58% | -967.38% | -396.61% | -385.19% | -185.29% | -149.32% | -230.19% |
| Total Other Income/Expenses | 9.82M | -3.35M | -2.11M | 1.30M | 3.96M | 4.06M | 1.34M | 1.11M | 605.00K | 642.00K | 579.00K | 2.88M | -737.00K | -210.00K | 50.00K | 5.02M | 26.14M | 16.00M | 4.18M | 880.00K | 297.00K | 0.00 | -11.91M | 0.00 | -23.40M | 2.70M | 1.80M | 1.80M |
| Income Before Tax | -184.13M | -141.90M | -116.11M | -75.62M | -68.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | 0.00 | -46.93M | 0.00 | -44.20M | -9.90M | -9.10M | -10.40M |
| Income Before Tax Ratio | -77,690.72% | -23,808.89% | -8,335.39% | -29,888.14% | -14,901.74% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | 0.00% | -1,296.38% | 0.00% | -818.52% | -145.59% | -124.66% | -196.23% |
| Income Tax Expense | 0.00 | -868.00K | 4.84M | -7.00K | -5.00M | 4.06M | 1.34M | 1.11M | 32.00K | 35.00K | 56.00K | -597.00K | 5.68M | 31.25M | -3.14M | -5.87M | -26.14M | -16.00M | -4.19M | 44.27M | -297.00K | -1.79M | 7.05M | 19.62M | 25.60M | -1.80M | -1.30M | -1.50M |
| Net Income | -184.13M | -141.03M | -120.95M | -75.61M | -63.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | -33.91M | -42.07M | -45.83M | -46.40M | -10.80M | -9.60M | -10.70M |
| Net Income Ratio | -77,690.72% | -23,663.26% | -8,682.84% | -29,885.38% | -13,815.43% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | -2,716.99% | -1,162.24% | -693.49% | -859.26% | -158.82% | -131.51% | -201.89% |
| EPS | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -2.08 |
| EPS Diluted | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -1.38 |
| Weighted Avg Shares Out | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 158.04M | 153.54M | 127.93M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 5.15M |
| Weighted Avg Shares Out (Dil) | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 162.66M | 153.54M | 128.38M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 7.74M |
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of transfusion-dependent anemia...
Buy biotech stock Geron for a 70% return in 12 months: Goldman Sachs
Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs analyst. Geron shares could shoot up to $4.0 Jenkins upgraded the biotech stock to “buy” on...
Geron Corporation: The FDA, Catalysts And New Competition From Old Drugs
GERN's New Drug Application for imetelstat in lower-risk myelodysplastic syndromes has been accepted for standard review by the FDA. The FDA's approval of Bristol-Myers Squibb's Reblozyl as a first-line treatment in lower-risk MDS may impact the positioning of imetelstat. Another...
Why Is Geron (GERN) Stock Up Today?
Geron (NASDAQ: GERN ) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares. Goldman Sachs analyst Corinne Jenkins is behind today's news by upgrading shares of GERN stock from a “neutral” rating to a “buy” rating.
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson's appointment follows the retirement of...
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced poster presentations of data from IMerge, the Company's Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat vs. placebo in patients with lower risk...
Geron to Participate in the Baird 2023 Global Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Baird 2023 Global...
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June...
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron's New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 189,850 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with...
Source: https://incomestatements.info
Category: Stock Reports